welcome
We are very excited to announce that the next 18th St.Gallen International Breast Cancer Conference 2023 will take place from 15 – 18 March 2023 in Vienna/ Austria.
Experts and literally all major breast cancer cooperative groups and centres worldwide, actively engaged in basic and clinical research as well as in clinical management of patients with breast cancer, will again present the latest data, critically reviewed by leading specialists in the field. The conference closes as usual with an update of the widely acknowledged «St. Gallen International Consensus on the optimal primary treatment of individuals with early breast cancer», which will be published only a few months after the conference.
We all look very much forward to be connected again with each other and to meet in Vienna. We are happy to draw your attention to the timeline right here:
> Wednesday, 1 June 2022
Opening early registration and hotel bookings
> Thursday, 1 September 2022
Opening poster and abstract submission
> Friday, 16 December 2022
Poster abstract submission deadline
> Friday, 16 December 2022
Early registration deadline
>Tuesday, 28 February 2023
Regular registration deadline
> Wednesday, 1 March 2023
Late registration fee applies
We are looking forward to meet many professionals in person again and will very much enjoy meeting old and new friends. For those professionals who will not be able to travel, we will have the possibility to access a virtual platform, with live streaming of all sessions and entry to a virtual exhibition.
Stay tuned and register below for the newsletter of the St.Gallen International Breast Conference 2023!
Your SG-BCC 2023 Organising Team
St.Gallen Oncology Conferences
Rorschacherstrasse 150, 9006 St.Gallen/Switzerland
sgbcc@oncoconferences.ch
www.sg-bcc.org
chairs
Meet our chairs:
Conference co-chairs
Univ. Prof. Dr. Michael Gnant, Medical University of Vienna / Austria
Prof. Dr. med. Beat Thürlimann, Breast Centre, Kantonsspital St.Gallen / Switzerland
Prof. Dr. Walter Weber, University Hospital Basel / Switzerland
Conference founder and honorary chair
Prof. Dr. med. Hans-Joerg Senn, c/o Tumor and Breast Center ZeTuP St.Gallen / Switzerland
Scientific Programme-Chairpersons
Harold Burstein, Boston/MA, USA
Giuseppe Curigliano, Milano/Italy
Michael Gnant, Vienna/Austria
Philip Poortmans, Antwerp/Belgium
Meredith Regan, Boston/MA, USA
Hans-Jörg Senn, St.Gallen/Switzerland
Beat Thürlimann, St.Gallen/Switzerland
Walter Weber, Basel/Switzerland
Eric Winer, Boston/MA, USA
conference programme
The 18th St.Gallen International Breast Cancer Conference 2023 will merge the best of the last conferences and is offering an innovative programme with a number of interactive sessions to allow for greater exchange between faculty and audiences.
Take a glance at the new programme to see what awaits you at next year’s conference and make sure to not miss any of the exciting themes!
> download the new SG-BCC 2023 programme format here
quick-links
> Wednesday, 15 March 2023
Industry sponsored symposium
Industry sponsored symposium
Industry sponsored symposium
Opening and award ceremony
Coffee break
Session 1: News in breast cancer care since SGBCC 2021
- Surgery of patients with early breast cancer: Quo vadis? (Walter Weber, Switzerland)
- Access to evidence based radiation therapy for patients with early breast cancer (Philip Poortmans, Belgium)
- What’s new in systemic treatment of patients with early breast cancer (tbc)
- Translational research priorities for patients with early breast cancer (tbc)
- Hot topics in survivorship, patient reported outcomes, and Qality of Life (Ann Partridge, USA)
Coffee break
Interactive Session I: How to avoid unnecessary mastectomies and unnecessary reconstructions – a global discussion
Welcome Apéro
> Thursday, 16 March 2023
Industry sponsored symposium
Session 2: Genomics, Transcriptomics, ctDNA for disease monitoring and risk stratification
- ctDNA dynamics for early assessment of recurrence risk (Nicholas Turner, UK)
- Molecular imaging in breast cancer (Elisabeth G. E. de Vries, Netherlands)
- Multi-omic machine learning prediction of treatment response (Carlos Caldas, Portugal)
- How to assess clinical utility and clinical validity of biomarkers in clinical trials? (Meredith Regan, USA)
Session 3: Immunology in early breast cancer
- Understanding the anti-cancer immune response: Innate and adaptive responses to cancer cells (Sherene Loi, Australia)
- Tumor microenvironment in early breast cancer (Carsten Denkert, Germany)
- Multiplexed analysis and spatial histology to predict response (Marleen Kok, Netherlands)
- The future of breast cancer immunotherapy (PD, PDL, vaccines) (Giuseppe Curigliano, Italy)
Lunch break
Industry sponsored symposium
Special lecture I and panel discussion
Panelists: Heba Gamal (Egypt), Shereen Loi (Australia), tbc
- The future of innovation: Why are we conducting clinical trials in countries that are unlikely to be able to afford innovative drugs? (Sara Tolaney, USA)
Session 4: Hereditary Breast Cancer
- Imaging, screening & surveillance for individuals with increased hereditary breast cancer risk (Suzette Delaloge, France)
- Local treatment in patients with high risk hereditary breast cancer (Maria Joao Cardoso, Portugal)
- Management of patients harboring medium penetrance genes (Christian Singer, Austria)
- Adjuvant therapy for BRCA carriers patients (Andrew Tutt, UK)
Session 5: The future treatment landscape in the adjuvant setting
- Post-neoadjuvant options in triple negative disease: PARPi, capecitabine, checkpoint inhibitors (Javier Cortes, Spain)
- Risk assessment in ER positive disease: Who should receive CDK 4-6 inhibitors? (tbc)
- What’s next? Antibody drug conjugates for breast cancer therapy (tbc)
- Integrating new oral SERDs in the adjuvant treatment (tbc)
Coffee break
Debate I: Early breast cancer: do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)?
Chairs: tbc
Debaters: Lisa Carey (USA), Nadia Harbeck (Germany)
Interactive Session II: Too big, too small? Too low, too high? Adjuvant choices when stage and biology do not align.
Chairs: tbc
What to do in discordant scenarios? Small tumors with high biological risk? (Case studies)
Coffee break
Industry sponsored symposium
> Friday, 17 March 2023
Industry sponsored symposium
Session 6: Tailoring breast surgery and radiotherapy
- Patient selection, dose and fractionation for external beam radiotherapy in patients with early breast cancer (Charlotte Coles, UK)
- Benefits and risks of immediate breast reconstruction after tumorectomy or mastectomy (Marie-Jeanne Vrancken Peeters, Netherlands)
- Breast surgery after neoadjuvant therapy (Andrea V. Barrio, USA)
- Breast surgery for local recurrence (Isabel Rubio, Spain)
Session 7: Controversies in the treatment of the axilla
- Axillary surgery in the adjuvant setting (Jana De Boniface, Sweden)
- Axillary surgery in the post-neoadjuvant setting (Oreste Gentilini, Italy)
- Current role of tailored and targeted axillary surgery approaches (Jörg Heil, Germany)
- De-escalation of axillary radiotherapy – the time has come! (Icro Meattini, Italy)
Lunch break
Industry sponsored symposium
Debate II: Axillary dissection versus axillary radiation for residual nodal disease
Chairs: tbc
Debaters: Monica Morrow (USA), Orit Kaidar-Person (Israel)
Interactive Session III: Controversies and uncertainties in axillary management
Coffee break
Session 8: Optimizing treatment in patients with HER2-positive breast cancer
- Assessing HER2 heterogeneity (tbc)
- Current adjuvant and neoadjuvant approaches (Nadia Harbeck, Germany)
- Emerging new treatments in HER2 positive breast cancer (Martine Piccart, Belgium)
- ER positive vs ER negative: tackling diversity in HER2 positive breast cancer (Aleix Prat, Spain)
Session 9: Optimizing treatment in patients with triple negative breast cancer
- Neoadjuvant and adjuvant treatment of patients with triple negative early breast cancer (tbc)
- Optimal chemotherapy in residual disease: carboplatin vs capecitabine (tbc)
- Tackling triple negative histological subtypes in early breast cancer (Jorge Reis Filho, USA)
- Can we de-escalate immunotherapy and chemotherapy in TNBC? (Hervè Bonnefoi, France)
Debate III: If you achieve pCR after neoadjuvant, do you need adjuvant therapy?
Chairs: tbc
Debaters: Sibylle Loibl (Germany), Steven Chia (Canada)
Coffee break
Industry sponsored symposium
> Saturday, 18 March 2023
Industry sponsored symposium
Session 10: Global Prespective on breast cancer treatment
- Breast cancer treatment and research from a global perspective (Benjamin Anderson, World Health Organization)
- Perspective from Asia (Binghe Xu, China)
- Perspective from Africa (Heba Gamal, Egypt)
- Perspective from Latin America (tbc)
Session 11: Optimizing treatment in patients with HR positive breast cancer
- Post-menopausal: Who needs chemotherapy in the neo (adjuvant) setting? (tbc)
- Pre-menopausal: Who needs chemotherapy in the neo (adjuvant) setting? (Prudence Francis, Australia)
- Can we omit adjuvant endocrine therapy? (tbc)
- Duration of endocrine therapy in early breast cancer (Jens Huober, Switzerland)
Lunch break
Debate IIII: Surgery of the primary for stage IV dissease
Chairs: tbc
Debaters: Rajendra Badwe (India), tbc
Special lecture II
Pushing the boundaries for cure – extending early BC to oligometastatic? (tbc)
St.Gallen International Consensus Session I
St.Gallen International Consensus Session on the optimal primary treatment of breast cancer 2023
> Seeking consensus on evidence and opinions
Coffee break
St.Gallen International Consensus Session II
St.Gallen International Consensus Session on the optimal primary treatment of breast cancer 2023
> Seeking consensus on evidence and opinions
Farewell
registration
The 18th St.Gallen International Breast Cancer Conference 2023 will return to the Austria Center Vienna from 15 – 18 March 2023. We already look forward to meet many professionals in person again and will very much enjoy meeting old and new friends. For those professionals who will not be able to travel, we will have the possibility to access a virtual platform, with live streaming of all sessions and entry to a virtual exhibition.
> Register here and secure your early-bird ticket on a reduced starting fee!
Registration fees:
| Early-bird fee until 16 December 2022 | Regular fee from 16 December 2022 | Late fee from 1 March 2023 | |
| Regular participant | EUR 790.00 | EUR 950.00 | EUR 1100.00 |
| Trainee* | EUR 480.00 | EUR 600.00 | EUR 720.00 |
| Allied health care professionals* | EUR 230.00 | EUR 300.00 | EUR 370.00 |
| Undergraduate students* | EUR 230.00 | EUR 300.00 | EUR 370.00 |
| Patient advocates* | EUR 230.00 | EUR 300.00 | EUR 370.00 |
| Emerging economies* | EUR 100.00 | EUR 100.00 | EUR 100.00 |
| Press | EUR 100.00 | EUR 100.00 | EUR 100.00 |
*Registration category definition:
| Trainee | The trainee fee is only applicable for master and PhD students as well as for young physicians in training. A certificate from the supervisor or head of department is required. |
| Allied health care professionals | The allied health professional fee applicable for professionals without a medical degree. A confirmation from the head of department is required. Allied Health Professionals include e.g. nutritionist, dieticians, psychologists, physiotherapists, and nurses |
| Undergraduate students | The undergraduate student fee is only applicable for medical students at university/college level who have not finished any medical degree yet. A certificate confirming the undergraduate student status required. |
| Patient advocates | Breast Cancer patients, individually or representing a patient advocacy group. A confirmation of the patient advocacy group may be requested. |
| Emerging economies | The emerging economies fee applies to individuals from low and lower-middle-income economies according to the World Bank listing (https://datahelpdesk.worldbank.org/knowledgebase/articles/906519) |
The registration fee includes:
- conference documentation
- participation in the conference programme – scientific sessions and sponsored industry symposia
- attendance at the opening ceremony & welcome apéro on 15 March 2023
- admission to the industrial exhibition
- coffee breaks
- public transportation ticket (valid from 15 to 18 March 2023)
- certificate of attendance upon submission of an online feedback questionnaire after the conference
- free virtual access to live stream and on-demand videos of selected scientific sessions (on-demand recordings will be accessible for a limited time after the congress)
> Register now and be part of this unique experience!
Important registration deadlines:
> Wednesday, 1 June 2022
Opening early registration
> Friday, 16 December 2022
Early registration deadline
>Tuesday, 28 February 2023
Regular registration deadline
> Wednesday, 1 March 2023
Late registration fee applies
Stay tuned and register below for the newsletter of the St.Gallen International Breast Conference 2023!
abstracts
St.Gallen Oncology Conferences has the mission to distribute the knowledge to improve quality care for women with early breast cancer worldwide. Your contribution can be a fundamental part of that claim. Abstract submission for the 18th St.Gallen International Breast Cancer Conference 2023 will open on 1 September 2022.
> Thursday, 1 September 2022
Opening poster and abstract submission> Friday, 16 December 2022
Poster abstract submission deadline
We already look forward to your contributions! The website will be updated with some more detailed information in due course.
Stay tuned and register below for the newsletter of the St.Gallen International Breast Cancer Conference 2023 so you won’t miss the latest news.
exhibition & sponsorship opportunities
Next year’s conference will merge the best of the last conferences – the 18th St.Gallen International Breast Cancer Conference is offering an innovative programme with a number of interactive sessions to allow for greater exchange between the faculty and audiences – it will give your company numerous opportunities to reach the community!
On the back of our successful virtual St.Gallen International Breast Cancer Conference 2021, we’ve decided that the 18th edition will increase accessibility and interactivity to further increase the outreach and educational mission of the Foundation SONK. For those professionals who will not be able to travel, we will have the possibility to access a virtual platform, with live streaming of all sessions and entry to a virtual exhibition.
- SG-BCC 2023 Sponsorship Opportunities
- Online application for exhibition and sponsorship
- Exhibition Package
- Satellite Symposia
- Other Sponsorship Opportunities
- Contact
1. SG-BCC 2023 Sponsorship Opportunities
Find all our exciting exhibition and sponsorship opportunities in the brochure:
> SG-BCC 2023 Sponsorship Opportunities
2. Online application for exhibition and sponsorship
To sign up for exhibition and sponsorship, you have to complete the online exhibition and sponsorship application form via the following link:
> Online application for exhibition and sponsorship
By completing the exhibition application form, companies agree to the SG-BCC 2023 Sponsorship & Exhibition Terms & Conditions. The booking is legally binding upon submission.
Below you can find a summarized but not exhaustive sponsorship opportunity list from our brochure.
3. Exhibition Package (min. 6 sqm)
Early-bird fee until Tuesday, 6 September 2022: € 550/ m2
Regular fee from Wednesday 7, September 2022: € 600/m2
Space allocation procedure will start in summer 2022 and will be done according to the following guidelines: total sponsorship contribution, booth size, date of application and payment of first deposit.
| Wednesday, 15 March 2023 | 08:30-09:30 | € 90,000 |
| Wednesday, 15 March 2023 | 10:00-11:00 | € 90,000 |
| Wednesday, 15 March 2023 | 11:30-12:30 | € 110,000 |
| Thursday, 16 March 2023 | 08:00-08:45 | € 90,000 |
| Thursday, 16 March 2023 | 11:30-12:30 | € 110,000 |
| Thursday, 16 March 2023 | 17:45-18:45 | € 100,000 |
| Friday, 17 March 2023 | 08:00-08:45 | € 90,000 |
| Friday, 17 March 2023 | 11:30-12:30 | € 110,000 |
| Friday, 17 March 2023 | 17:45-18:45 | € 100,000 |
Complete the Online Exhibition and Sponsorship Application to reserve your preferred time slot. Bookings must be submitted and will only be accepted via the online application. No options can be reserved. More details an information in the SG-BCC 2023 industry brochure above.
Included benefits:
- Use of the main auditorium
- Broadcast of the live Satellite Symposia on the Virtual Platform
- Publication of symposium programme
- One push notification
- One mailing sent to all registered participants
- 10% discount on the exhibition space
- 5 Full conference registrations
More details and information can be found in the SG-BCC 2023 industry brochure above.
5. Many other sponsorship opportunities
- Lanyards
- Conference App
- Water bottle for delegates
- Sitting cubes
- Digital advert on the virtual conference platform
- Video advertising spot
- Mailing to participants
- Article in the SG-BCC newsletters
More details and information can be found in the SG-BCC 2023 industry brochure above.
If you have any questions please get in contact with:
Ellen Valckenaere
Senior Industry Relations Manager
Mondial Congress & Events
valckenaere@mondial-congress.com
contact
St. Gallen Oncology Conferences (SONK)
Rorschacherstrasse 150
9006 St.Gallen / Switzerland
+41 71 243 09 90
sgbcc@oncoconferences.ch
the St.Gallen Consensus on the optimal Treatment of women with early breast cancer
The St.Gallen International Breast Cancer Conference 2021 closed as usual with an update of the widely acknowledged St.Gallen International Breast Cancer Consensus on the optimal Treatment of Women with early breast cancer.
In order to allow even more room for discussions on early breast cancer care, the 2021 Consensus Session took place on two days, 20 and 21 March 2021. For the first time ever, the consensus panel decided that they want to hear the questions of the audience directly, who made good use of the new Q&A Tool.
The list of all members of the St.Gallen 2021 International Breast Cancer Consensus panel can be found here.
Publication 2021
The consensus and its related scientific core issues are now available online in a special article of the Annals of Oncology:
Publications 2019:
Estimating the benefits of therapy for early-stage breast cancer: read the St.Gallen International Consensus Guidelines for the Primary therapy of early breast cancer 2019 here.
webcasts
Click on the links below to view the webcasts of the St.Gallen International Breast Cancer Conferences of the previous years: